drugset
drugset / Trial / NCT00004263

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00004263 ↗

Phase 1 Completed 16 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. UCN-01 may make cancer cells more sensitive to cytarabine. PURPOSE: Phase I trial to study the effectiveness of cytarabine and UCN-01 in treating patients who have refractory or relapsed acute myelogenous leukemia or myelodysplastic syndrome.

Timeline

Start
1999-12
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 1 g Intravenous
Subject UCN-01 Small molecule 20 mg/m2 Intravenous

Indications

leukemia myelodysplastic syndrome